PURPOSE OF REVIEW: Alzheimer disease (AD) is the most common cause of late-onset dementia. This article describes the epidemiology, genetic and environmental risk factors, clinical diagnosis, biomarkers, and treatment of late-onset AD, defined by age of onset of 65 years or older. RECENT FINDINGS: An estimated 5.7 million Americans are living with AD dementia, with the number of affected individuals growing rapidly because of an aging population. Vascular risk factors, sleep disorders, and traumatic brain injury are associated with an increased risk of AD, while increased cognitive and physical activity throughout the lifespan reduce the risk of disease. The primary genetic risk factor for late-onset AD is the apolipoprotein E (APOE) ε4 allele. AD typically presents with early and prominent episodic memory loss, although this clinical syndrome is neither sensitive nor specific for underlying AD neuropathology. Emerging CSF and imaging biomarkers can now detect the key neuropathologic features of the disease (amyloid plaques, neurofibrillary tangles, and neurodegeneration) in living people, allowing for characterization of patients based on biological measures. A comprehensive treatment plan for AD includes use of symptomatic medications, optimal treatment of comorbid conditions and neuropsychiatric symptoms, counseling about safety and future planning, and referrals to community resources. SUMMARY: AD is very common in older neurologic patients. Neurologists should set the standard for the diagnosis and care of patients with AD and should be familiar with emerging biomarkers that have transformed AD research and are primed to enter the clinical arena.
PURPOSE OF REVIEW: Alzheimer disease (AD) is the most common cause of late-onset dementia. This article describes the epidemiology, genetic and environmental risk factors, clinical diagnosis, biomarkers, and treatment of late-onset AD, defined by age of onset of 65 years or older. RECENT FINDINGS: An estimated 5.7 million Americans are living with AD dementia, with the number of affected individuals growing rapidly because of an aging population. Vascular risk factors, sleep disorders, and traumatic brain injury are associated with an increased risk of AD, while increased cognitive and physical activity throughout the lifespan reduce the risk of disease. The primary genetic risk factor for late-onset AD is the apolipoprotein E (APOE) ε4 allele. AD typically presents with early and prominent episodic memory loss, although this clinical syndrome is neither sensitive nor specific for underlying AD neuropathology. Emerging CSF and imaging biomarkers can now detect the key neuropathologic features of the disease (amyloid plaques, neurofibrillary tangles, and neurodegeneration) in living people, allowing for characterization of patients based on biological measures. A comprehensive treatment plan for AD includes use of symptomatic medications, optimal treatment of comorbid conditions and neuropsychiatric symptoms, counseling about safety and future planning, and referrals to community resources. SUMMARY:AD is very common in older neurologic patients. Neurologists should set the standard for the diagnosis and care of patients with AD and should be familiar with emerging biomarkers that have transformed AD research and are primed to enter the clinical arena.
Authors: Matthew Baumgart; Heather M Snyder; Maria C Carrillo; Sam Fazio; Hye Kim; Harry Johns Journal: Alzheimers Dement Date: 2015-06-01 Impact factor: 21.566
Authors: Claudia H Kawas; Ronald C Kim; Joshua A Sonnen; Szofia S Bullain; Thomas Trieu; María M Corrada Journal: Neurology Date: 2015-07-15 Impact factor: 9.910
Authors: Rik Ossenkoppele; Willemijn J Jansen; Gil D Rabinovici; Dirk L Knol; Wiesje M van der Flier; Bart N M van Berckel; Philip Scheltens; Pieter Jelle Visser; Sander C J Verfaillie; Marissa D Zwan; Sofie M Adriaanse; Adriaan A Lammertsma; Frederik Barkhof; William J Jagust; Bruce L Miller; Howard J Rosen; Susan M Landau; Victor L Villemagne; Christopher C Rowe; Dong Y Lee; Duk L Na; Sang W Seo; Marie Sarazin; Catherine M Roe; Osama Sabri; Henryk Barthel; Norman Koglin; John Hodges; Cristian E Leyton; Rik Vandenberghe; Koen van Laere; Alexander Drzezga; Stefan Forster; Timo Grimmer; Pascual Sánchez-Juan; Jose M Carril; Vincent Mok; Vincent Camus; William E Klunk; Ann D Cohen; Philipp T Meyer; Sabine Hellwig; Andrew Newberg; Kristian S Frederiksen; Adam S Fleisher; Mark A Mintun; David A Wolk; Agneta Nordberg; Juha O Rinne; Gaël Chételat; Alberto Lleo; Rafael Blesa; Juan Fortea; Karine Madsen; Karen M Rodrigue; David J Brooks Journal: JAMA Date: 2015-05-19 Impact factor: 56.272
Authors: Philip S Wang; Sebastian Schneeweiss; Jerry Avorn; Michael A Fischer; Helen Mogun; Daniel H Solomon; M Alan Brookhart Journal: N Engl J Med Date: 2005-12-01 Impact factor: 91.245
Authors: Bryan D James; Robert S Wilson; Patricia A Boyle; John Q Trojanowski; David A Bennett; Julie A Schneider Journal: Brain Date: 2016-11-01 Impact factor: 13.501
Authors: Clifford R Jack; David A Bennett; Kaj Blennow; Maria C Carrillo; Billy Dunn; Samantha Budd Haeberlein; David M Holtzman; William Jagust; Frank Jessen; Jason Karlawish; Enchi Liu; Jose Luis Molinuevo; Thomas Montine; Creighton Phelps; Katherine P Rankin; Christopher C Rowe; Philip Scheltens; Eric Siemers; Heather M Snyder; Reisa Sperling Journal: Alzheimers Dement Date: 2018-04 Impact factor: 21.566
Authors: Luigi Lorenzini; Loes T Ansems; Isadora Lopes Alves; Silvia Ingala; David Vállez García; Jori Tomassen; Carole Sudre; Gemma Salvadó; Mahnaz Shekari; Gregory Operto; Anna Brugulat-Serrat; Gonzalo Sánchez-Benavides; Mara Ten Kate; Betty Tijms; Alle Meije Wink; Henk J M M Mutsaerts; Anouk den Braber; Pieter Jelle Visser; Bart N M van Berckel; Juan Domingo Gispert; Frederik Barkhof; Lyduine E Collij Journal: Brain Commun Date: 2022-06-15
Authors: Xi Pan; Donglan Zhang; Ji Haeng Heo; Chanhyun Park; Gang Li; Christine M Dengler-Crish; Yan Li; Yian Gu; Henry N Young; Devin L Lavender; Lu Shi Journal: Drugs Aging Date: 2022-10-17 Impact factor: 4.271